Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer
Background This meta-analysis seeks to assess the efficacy and safety of pembrolizumab in individuals with advanced or recurrent cervical cancer.Methods Databases from PubMed, Embase, and the Cochrane Library were all thoroughly searched for pertinent research. Outcomes include complete response (CR...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Obstetrics and Gynaecology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/01443615.2024.2390564 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553147865071616 |
|---|---|
| author | Xue Zhang Wen-Jie Yin Ai-Li Zhang Xiao-Xiao Zhang Li-Juan Ding Jiao Zhang Shu-Ting He Jie-Ping Yan |
| author_facet | Xue Zhang Wen-Jie Yin Ai-Li Zhang Xiao-Xiao Zhang Li-Juan Ding Jiao Zhang Shu-Ting He Jie-Ping Yan |
| author_sort | Xue Zhang |
| collection | DOAJ |
| description | Background This meta-analysis seeks to assess the efficacy and safety of pembrolizumab in individuals with advanced or recurrent cervical cancer.Methods Databases from PubMed, Embase, and the Cochrane Library were all thoroughly searched for pertinent research. Outcomes include complete response (CR), partial response (PR), stable disease (SD), disease progression (PD), overall response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and adverse events (AEs) were retrieved for further analysis.Results Ten trials with 721 patients were included in this meta-analysis. The pooled results for patients with cervical cancer receiving pembrolizumab were as follows: CR (0.06, 95%CI: 0.02–0.10), PR (0.15, 95%CI: 0.08–0.22), SD (0.16, 95%CI: 0.13–0.20), PD (0.50, 95%CI: 0.25–0.75), ORR (0.26, 95%CI: 0.11–0.41) and DCR (0.42, 95%CI: 0.13–0.71), respectively. Regarding survival analysis, the pooled mPFS and mOS were 3.81 and 10.15 months. Subgroup analysis showed that pembrolizumab in combination was more beneficial in CR (0.16 vs. 0.03, p = 0.012), PR (0.24 vs. 0.08, p = 0.032), SD (0.11 vs. 0.19, p = 0.043), ORR (0.42 vs. 0.11, p = 0.014), and mPFS (5.54 months vs. 2.27 months, p < 0.001) than as single agent. The three most common AEs were diarrhoea (0.25), anaemia (0.25), and nausea (0.21), and the incidence of grade 3–5 AEs was significantly lower, rarely surpassing 0.10.Conclusions For patients with advanced or recurrent cervical cancer, this systematic review and meta-analysis demonstrated that pembrolizumab had a favourable efficacy and tolerability. Future research will primarily focus on optimising customised regiments that optimally integrate pembrolizumab into new therapies and combination strategies. Designed to maximise patient benefit and efficiently control adverse effects while maintaining a high standard of living. |
| format | Article |
| id | doaj-art-5aab0fc7ae49432386ac71b0f9a8efa2 |
| institution | Kabale University |
| issn | 0144-3615 1364-6893 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Obstetrics and Gynaecology |
| spelling | doaj-art-5aab0fc7ae49432386ac71b0f9a8efa22025-01-09T12:13:17ZengTaylor & Francis GroupJournal of Obstetrics and Gynaecology0144-36151364-68932024-12-0144110.1080/01443615.2024.2390564Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancerXue Zhang0Wen-Jie Yin1Ai-Li Zhang2Xiao-Xiao Zhang3Li-Juan Ding4Jiao Zhang5Shu-Ting He6Jie-Ping Yan7Department of Pharmacy, Kunming Yan’an Hospital, Yan’an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, ChinaDepartment of Pharmacy, Kunming Yan’an Hospital, Yan’an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, ChinaDepartment of Pharmacy, Kunming Yan’an Hospital, Yan’an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, ChinaDepartment of Pharmacy, Kunming Yan’an Hospital, Yan’an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, ChinaDepartment of Pharmacy, Kunming Yan’an Hospital, Yan’an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, ChinaDepartment of Basic Medicine, Zhaotong Health Vocational College, Zhaotong, Yunnan, ChinaCollege of Pharmacy, Dali University, Dali, Yunnan, ChinaCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, ChinaBackground This meta-analysis seeks to assess the efficacy and safety of pembrolizumab in individuals with advanced or recurrent cervical cancer.Methods Databases from PubMed, Embase, and the Cochrane Library were all thoroughly searched for pertinent research. Outcomes include complete response (CR), partial response (PR), stable disease (SD), disease progression (PD), overall response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and adverse events (AEs) were retrieved for further analysis.Results Ten trials with 721 patients were included in this meta-analysis. The pooled results for patients with cervical cancer receiving pembrolizumab were as follows: CR (0.06, 95%CI: 0.02–0.10), PR (0.15, 95%CI: 0.08–0.22), SD (0.16, 95%CI: 0.13–0.20), PD (0.50, 95%CI: 0.25–0.75), ORR (0.26, 95%CI: 0.11–0.41) and DCR (0.42, 95%CI: 0.13–0.71), respectively. Regarding survival analysis, the pooled mPFS and mOS were 3.81 and 10.15 months. Subgroup analysis showed that pembrolizumab in combination was more beneficial in CR (0.16 vs. 0.03, p = 0.012), PR (0.24 vs. 0.08, p = 0.032), SD (0.11 vs. 0.19, p = 0.043), ORR (0.42 vs. 0.11, p = 0.014), and mPFS (5.54 months vs. 2.27 months, p < 0.001) than as single agent. The three most common AEs were diarrhoea (0.25), anaemia (0.25), and nausea (0.21), and the incidence of grade 3–5 AEs was significantly lower, rarely surpassing 0.10.Conclusions For patients with advanced or recurrent cervical cancer, this systematic review and meta-analysis demonstrated that pembrolizumab had a favourable efficacy and tolerability. Future research will primarily focus on optimising customised regiments that optimally integrate pembrolizumab into new therapies and combination strategies. Designed to maximise patient benefit and efficiently control adverse effects while maintaining a high standard of living.https://www.tandfonline.com/doi/10.1080/01443615.2024.2390564Pembrolizumabcervical cancerprogression-free survivaloverall survivaladverse events |
| spellingShingle | Xue Zhang Wen-Jie Yin Ai-Li Zhang Xiao-Xiao Zhang Li-Juan Ding Jiao Zhang Shu-Ting He Jie-Ping Yan Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer Journal of Obstetrics and Gynaecology Pembrolizumab cervical cancer progression-free survival overall survival adverse events |
| title | Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer |
| title_full | Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer |
| title_fullStr | Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer |
| title_full_unstemmed | Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer |
| title_short | Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer |
| title_sort | meta analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer |
| topic | Pembrolizumab cervical cancer progression-free survival overall survival adverse events |
| url | https://www.tandfonline.com/doi/10.1080/01443615.2024.2390564 |
| work_keys_str_mv | AT xuezhang metaanalysisofefficacyandsafetyofpembrolizumabforthetreatmentofadvancedorrecurrentcervicalcancer AT wenjieyin metaanalysisofefficacyandsafetyofpembrolizumabforthetreatmentofadvancedorrecurrentcervicalcancer AT ailizhang metaanalysisofefficacyandsafetyofpembrolizumabforthetreatmentofadvancedorrecurrentcervicalcancer AT xiaoxiaozhang metaanalysisofefficacyandsafetyofpembrolizumabforthetreatmentofadvancedorrecurrentcervicalcancer AT lijuanding metaanalysisofefficacyandsafetyofpembrolizumabforthetreatmentofadvancedorrecurrentcervicalcancer AT jiaozhang metaanalysisofefficacyandsafetyofpembrolizumabforthetreatmentofadvancedorrecurrentcervicalcancer AT shutinghe metaanalysisofefficacyandsafetyofpembrolizumabforthetreatmentofadvancedorrecurrentcervicalcancer AT jiepingyan metaanalysisofefficacyandsafetyofpembrolizumabforthetreatmentofadvancedorrecurrentcervicalcancer |